|
|
|
|
New option for cardio protection
Antihypertensive agent Micardis (telmisartan) 80mg has been approved for the prevention of cardiovascular morbidity and mortality in patients with vascular disease or high-risk diabetes.Pharmacists can now advise patients 55 years or older with a...
|
|
|
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Galzerano D et al.Telmisartan is an angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure. In patients with...
|
|
|
Withdrawn application for approval of additional indication for type 2 diabetic incipient nephropathy for 'Mic
- Astellas Pharma Inc.(Astellas Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi Nogimori) announced today the withdrawal of the application for approval of additional indication for type 2 diabetic incipient nephropathy for MicardisTablets...
|
|
|
Bayer pharma sales overcome European decline
Bayers group sales dropped 5% to 31 billion euros in a difficult year for the company that saw a drop in European pharma sales compounded by the impact of the recession.But the companys pharma and consumer health divisions bucked this trend with combined...
|
|
|
Astellas Pharma Withdraws Application For Type 2 Diabetes Drug
Astellas Pharma has withdrawn the application for approval of additional indication for type 2 diabetic incipient nephropathy for 'Micardis tablets'(generic name: telmisartan), angiotensin II receptor blocker which is co-promoted with Nippon Boehringer...
|
|
|
Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats
Hypertension Research 33, 135 (February 2010).doi:10.1038/hr.2009. Telmisartan improves endothelial dysfunction and renal autoregulation in Dahl salt-sensitive rats.
|
|
|
Micardis approved to reduce cardiovascular risk
ngelheim wish to announce that the European Commission has approved Micardis (telmisartan) for the reduction of cardiovascular morbidity in patients with: I.manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or...
|
|
|
New Research Report: Malaysia Pharmaceuticals & Healthcare Report Q1 2010
In BMI's Business Environment Rating (BER) matrix for Q409, Malaysia considerably improved its position in the Asia Pacific matrix, and is now ranked fifth out of the 15 key regional markets.Key attractions of the Malaysian pharmaceutical market are the...
|
|
|
A Hypertension Drug Requiring Less-Frequent Dosing Than Novartis's Diovan/Tareg Would Earn Similar Patient Share in Europe and U.S.
The Fixed-Dose Combination Telmisartan/Amlodipine Will Become the New Decision Resources Clinical Gold Standard for Hypertension in 2013 WALTHAM, Mass., Jan.7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for...
|
